<DOC>
	<DOC>NCT00230503</DOC>
	<brief_summary>- Compare the safety of four oral doses of pradefovir after 48 weeks of treatment - Select the dose of pradefovir for Phase 3 studies</brief_summary>
	<brief_title>Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B</brief_title>
	<detailed_description>- Compare the safety of four oral doses of pradefovir after 48 weeks of treatment - Compare the antiviral activity of four oral doses of pradefovir to adefovir and dipivoxyl after 48 weeks of treatment - Select the dose of pradefovir for Phase 3 studies - Determine the pharacokinetic profiles of four oral doses of pradefovir</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<criteria>Compensated chronic HBV Infection No prior treatment with adefovir dipivoxil No interferon or lamivudine treatment for three months prior to enrollment HBeAg positive or negative HBV DNA viral load greater than 500,000 copies per mL ALT between 1.2 and 10 times ULN Positive HIV, HCV, and/or HDV serology History of renal tubular necrosis Serum creatinine greater than 2.0 mg/dl History of organ transplant or use of immunosuppresive drugs Pregnant or breastfeeding females</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Hepatitis B, Chronic</keyword>
	<keyword>Hepatitis B Virus</keyword>
	<keyword>Pradefovir Mesylate</keyword>
	<keyword>Adefovir Dipivoxyl</keyword>
</DOC>